Psoriasis research has accelerated significantly over the past five years. The pipeline of treatments is broader than it has ever been, the science of why psoriasis behaves as it does is better understood, and several research directions that looked promising a decade ago are now producing clinical results. This article covers the five most significant areas of active research — what the evidence currently shows, what's still being established, and what it means practically for people managing psoriasis today.
New non-steroidal topicals — roflumilast and the PDE4 class
The most significant recent development in topical psoriasis treatment is the emergence of phosphodiesterase-4 (PDE4) inhibitors — a mechanism that targets inflammation at the cellular level without the skin-thinning risks associated with corticosteroids. This matters practically because topical steroids, while effective short-term, carry restrictions on duration of use and body area, particularly for sensitive areas like the scalp, face, and skin folds.
Roflumilast foam 0.3% (Zoryve) — scalp and body psoriasis
The FDA approved roflumilast topical foam 0.3% for plaque psoriasis of the scalp and body in adults and adolescents aged 12 and older in May 2025, based on results from the phase 3 ARRECTOR trial (432 patients) and phase 2 Trial 204 (combined enrollment of 736).[1]
In the ARRECTOR trial, 66.4% of patients treated with roflumilast foam achieved Scalp-IGA success (clear or almost clear, plus ≥2-grade improvement from baseline) at 8 weeks, compared to 27.8% with vehicle. Body-IGA success: 45.5% vs 20.1%. Itch relief was measurable within 24 hours of the first application.[1]
Significance for patients: roflumilast has no restriction on duration of use, no skin-thinning risk, and is approved for application to hair-bearing and sensitive areas where steroids are problematic. It is a prescription treatment — not available OTC — and is manufactured by Arcutis Biotherapeutics.
Roflumilast cream 0.3% for plaque psoriasis (applied to body, including intertriginous areas) received FDA approval in December 2024 for patients aged 6 and older. An application to extend approval to children aged 2–5 was accepted by the FDA in late 2025 with a PDUFA target date of June 2026. The PDE4 inhibitor class is still expanding.
PDE4 inhibitors don't replace steroids — they complement them by providing a steroid-free option for maintenance, sensitive areas, and long-term use. For patients who have managed scalp psoriasis with coal tar shampoos and find them effective, roflumilast addresses a different part of the same problem: it is prescription-only and works through a different mechanism (PDE4 inhibition vs. anti-proliferative and anti-inflammatory action of coal tar). They are not mutually exclusive.
Biologics and biosimilars — the current landscape
Biologic treatments — injectable medications that target specific immune signaling proteins involved in psoriatic inflammation — remain the most effective option for moderate-to-severe psoriasis. The primary targets are IL-17 (secukinumab, ixekizumab, bimekizumab), IL-23 (guselkumab, risankizumab, tildrakizumab), and TNF-α (adalimumab, etanercept). IL-17 and IL-23 inhibitors represent the current leading edge, with 75–90% skin clearance rates in clinical trials.
The most significant development in the biologics landscape in recent years is the expansion of biosimilars — lower-cost versions of established biologics that have demonstrated equivalent safety and efficacy. Adalimumab biosimilars in particular have substantially reduced the cost barrier for one of the most widely prescribed biologics. This is a practical shift for patients who have been unable to access biologic treatment due to cost.
Biologics are reserved for moderate-to-severe psoriasis (typically PASI ≥10 or significant quality of life impact) that hasn't responded adequately to topical treatment and/or phototherapy. They require injection (most are self-administered) and regular monitoring. They are not appropriate for mild-to-moderate psoriasis. The biosimilar expansion primarily affects access for people already in the biologic treatment pathway.
The gut-skin axis — from hypothesis to mechanism
Five years ago, the connection between gut microbiome and psoriasis was largely observational — studies showing differences in gut bacteria between people with psoriasis and healthy controls, with limited understanding of mechanism. That has changed materially. The specific pathways by which gut dysbiosis influences psoriatic inflammation are now documented at a mechanistic level: depleted short-chain fatty acid production (particularly butyrate), disrupted tryptophan metabolism producing pro-inflammatory rather than anti-inflammatory metabolites, and increased intestinal permeability allowing bacterial components to enter circulation and trigger systemic immune activation.[2]
This has shifted the gut-skin axis from an interesting observation to an active therapeutic target. Current research directions include probiotic interventions with specific strains targeting psoriasis-relevant immune pathways, dietary interventions (particularly Mediterranean diet and high-fiber diets) with microbiome endpoints, and early-stage fecal microbiota transplantation trials in psoriatic arthritis populations.
The practical implication today is the dietary side: supporting gut microbiome diversity through fiber-rich, fermented food-inclusive eating has documented effects on the inflammatory mechanisms relevant to psoriasis. The more targeted interventions — specific probiotic strains, FMT — are still at early-stage research with limited clinical application. The mechanism is established; the therapeutic interventions are being established.
Natural formulations — what the research shows
Interest in botanical and mineral-based psoriasis treatments has grown as patients increasingly seek alternatives to steroids for long-term management. The research base for natural treatments is uneven — some have decades of evidence, others have emerging research, and some have community popularity with limited clinical support.
Coal tar
The most established natural-derived treatment for psoriasis, with over a century of documented use and a well-characterized mechanism: anti-proliferative effects on keratinocytes, reduction of DNA synthesis in rapidly dividing skin cells, and anti-inflammatory properties. Its continued relevance in 2024–2026 research is specifically as a long-term OTC option — it does not carry the skin-thinning risks of steroids or the systemic exposure concerns of newer prescription treatments. Recent research interest centers on refined formulations that preserve efficacy while improving tolerability and cosmetic acceptability.
Curcumin
The active compound in turmeric has documented inhibitory effects on NF-κB, the transcription factor central to psoriatic inflammatory signaling. A 2015 randomized controlled trial (Antiga et al., JAMA Dermatology) showed that oral curcumin in a bioavailable formulation (Meriva) produced measurable reductions in PASI scores and IL-22 serum levels when used as an adjunct to topical treatment. The key limitation is bioavailability — standard curcumin powder is poorly absorbed, and the clinical benefit depends on the delivery formulation.
Magnesium
Emerging research has examined the relationship between magnesium status and psoriasis. A 2024 PubMed review found associations between lower magnesium levels and inflammatory skin conditions, and early clinical observations suggest that magnesium baths may reduce scaling and irritation.[3] The evidence base is preliminary — randomized controlled trial data is limited. This is an area to watch rather than an established intervention.
The strongest evidence for natural-derived treatments in psoriasis is for coal tar (decades of documented use, established mechanism) and omega-3 fatty acids (replicated evidence across multiple studies). Curcumin has solid mechanistic rationale and one well-designed RCT. Magnesium is promising but early. The research trend — toward confirming mechanisms for natural compounds through rigorous clinical trials — is positive for this class of treatments generally.
AI and technology in psoriasis management
Artificial intelligence applications in dermatology have advanced from conceptual to practical over the past three years. The most developed applications are diagnostic support tools — algorithms trained on large datasets of dermoscopy and clinical images that can identify and classify psoriasis lesions with accuracy approaching specialist dermatologists in controlled settings. This is relevant primarily in primary care and underserved settings where specialist access is limited.
In active development: AI-assisted PASI scoring (replacing the variability of manual scoring with consistent algorithmic assessment), predictive modeling for treatment response based on patient biomarker profiles, and patient-facing apps that track flare patterns against diet, stress, sleep, and weather data. None of these are in mainstream clinical use yet, but the progression from research tools to clinical tools is well underway.
AI is not prescribing treatment, identifying individual triggers with clinical reliability, or replacing the clinical judgment of a dermatologist. The practical value for patients today is limited — the most useful tools are basic symptom trackers, which don't require AI. The technology's near-term clinical impact will be on diagnosis accuracy and treatment matching in healthcare settings, not in direct consumer tools.
The overall trajectory of psoriasis research points toward more targeted treatments with fewer systemic side effects, better understanding of individual variation in triggers and treatment response, and a growing role for lifestyle and microbiome factors alongside pharmaceutical management. No single development represents a cure — but the combination of better prescription options, clearer dietary evidence, and improving natural formulations means the range of effective tools available to people managing psoriasis continues to expand.
The research confirms what 20+ years of Nopsor customers already know
Coal tar and salicylic acid in a nightly two-step system — the same mechanism that research continues to validate as a long-term, steroid-free option. Eight botanical herbs. No prescription needed.
See the Nopsor Treatment Set →40-day money-back guarantee · No prescription needed
References
- Gooderham M.J. et al. — Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial. JAMA Dermatology, 2025; 161(7):698–706. pubmed.ncbi.nlm.nih.gov/40332898
- Zhu Q. et al. — Advances in psoriasis and gut microorganisms with co-metabolites. Frontiers in Microbiology, 2023; 14:1192543. pubmed.ncbi.nlm.nih.gov/38033573
- Veronese N. et al. — Role of magnesium in skin disorders: a focus on psoriasis. Nutrients, 2024. pubmed.ncbi.nlm.nih.gov/39485525
Leave a comment
Also in Psoriasis Research and Trends
Is There a Cure for Psoriasis? What the Research Shows
August 13, 2025
No cure exists for psoriasis at this time — but that answer requires context. This article explains why psoriasis is resistant to permanent cure, the meaningful difference between cure and remission, and where the four most promising research directions stand today: biologics, gene therapy, gut microbiome, and AI.
Continue reading